retatrutide phase 2 trial obesity nejm 2023 VisualAbstract: reduces body weight by 17.5% in patients with retatrutide phase 2 nejm 2023

This enables a semi-permanent, just-eaten sensation of fullness that consequently leads to decreased food intake and, ultimately, weight loss

How to prepare before your appointment Preparation wins prescriptions

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R

The lubricant coating on the needle degrades

"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line"

Next-generation therapies, which include combinations of GLP-1 drugs and other peptides, are being studied for their potential to better preserve muscle and bone compared with GLP-1 drugs alone